Comprehensive assessment of the effectiveness of l-carnitine and transresveratrol in rats with diet-induced obesity

Шипелин, В А; Трусов, Н В; Apryatin, S A; Шумакова, А А; Timonin, A N; Ригер, Н. А.; Gmoshinski, I. V.; Nikityuk, D. B.

doi:10.1016/j.nut.2021.111561

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study showed that resveratrol supplementation significantly affects lipid regulation in obese patients [ 47 ]. In diet-induced obese rats, resveratrol also affected blood lipids and inflammatory responses to reduce the rat body weight [ 72 ]. After receiving resveratrol treatment, the obese mice’s gut microbiota composition was drastically changed [ 73 ].…”

Section: Dietary Polyphenols’ Impact On Obesitymentioning

confidence: 99%

Targeting mTOR Signaling by Dietary Polyphenols in Obesity Prevention

Cao

Han

et al. 2022

Nutrients

View full text Add to dashboard Cite

Dietary polyphenols can be utilized to treat obesity and chronic disorders linked to it. Dietary polyphenols can inhibit pre-adipocyte proliferation, adipocyte differentiation, and triglyceride accumulation; meanwhile, polyphenols can also stimulate lipolysis and fatty acid β-oxidation, but the molecular mechanisms of anti-obesity are still unclear. The mechanistic target of rapamycin (mTOR) is a protein kinase that regulates cell growth, survival, metabolism, and immunity. mTOR signaling is also thought to play a key role in the development of metabolic diseases such as obesity. Recent studies showed that dietary polyphenols could target mTOR to reduce obesity. In this review, we systematically summarized the research progress of polyphenols in preventing obesity through the mTOR signaling pathway. Mechanistically, polyphenols can target multiple signaling pathways and gut microbiota to regulate the mTOR signaling pathway to exert anti-obesity effects. The main mechanisms include: modulating lipid metabolism, adipogenesis, inflammation, etc. Dietary polyphenols exerting an anti-obesity effect by targeting mTOR signaling will broaden our understanding of the anti-obesity mechanisms of polyphenols and provide valuable insights for researchers in this novel field.

show abstract

Section: Dietary Polyphenols’ Impact On Obesitymentioning

confidence: 99%

Targeting mTOR Signaling by Dietary Polyphenols in Obesity Prevention

Cao

Han

et al. 2022

Nutrients

View full text Add to dashboard Cite

show abstract

The effects of L-carnitine supplementation on glycemic markers in adults: A systematic review and dose-response meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background and aimsHyperglycemia and insulin resistance are concerns today worldwide. Recently, L-carnitine supplementation has been suggested as an effective adjunctive therapy in glycemic control. Therefore, it seems important to investigate its effect on glycemic markers.MethodsPubMed, Scopus, Web of Science, and the Cochrane databases were searched in October 2022 for prospective studies on the effects of L-carnitine supplementation on glycemic markers. Inclusion criteria included adult participants and taking oral L-carnitine supplements for at least seven days. The pooled weighted mean difference (WMD) was calculated using a random-effects model.ResultsWe included the 41 randomized controlled trials (RCTs) (n = 2900) with 44 effect sizes in this study. In the pooled analysis; L-carnitine supplementation had a significant effect on fasting blood glucose (FBG) (mg/dl) [WMD = −3.22 mg/dl; 95% CI, −5.21 to −1.23; p = 0.002; I2 = 88.6%, p < 0.001], hemoglobin A1c (HbA1c) (%) [WMD = −0.27%; 95% CI, −0.47 to −0.07; p = 0.007; I2 = 90.1%, p < 0.001] and homeostasis model assessment-estimate insulin resistance (HOMA-IR) [WMD = −0.73; 95% CI, −1.21 to −0.25; p = 0.003; I2 = 98.2%, p < 0.001] in the intervention compared to the control group. L-carnitine supplementation had a reducing effect on baseline FBG ≥100 mg/dl, trial duration ≥12 weeks, intervention dose ≥2 g/day, participants with overweight and obesity (baseline BMI 25–29.9 and >30 kg/m2), and diabetic patients. Also, L-carnitine significantly affected insulin (pmol/l), HOMA-IR (%), and HbA1c (%) in trial duration ≥12 weeks, intervention dose ≥2 g/day, and participants with obesity (baseline BMI >30 kg/m2). It also had a reducing effect on HOMA-IR in diabetic patients, non-diabetic patients, and just diabetic patients for insulin, and HbA1c. There was a significant nonlinear relationship between the duration of intervention and changes in FBG, HbA1c, and HOMA-IR. In addition, there was a significant nonlinear relationship between dose (≥2 g/day) and changes in insulin, as well as a significant linear relationship between the duration (weeks) (coefficients = −16.45, p = 0.004) of intervention and changes in HbA1C.ConclusionsL-carnitine could reduce the levels of FBG, HbA1c, and HOMA-IR.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier: CRD42022358692.

show abstract

Comprehensive assessment of the effectiveness of l-carnitine and transresveratrol in rats with diet-induced obesity

Cited by 2 publications

References 45 publications

Targeting mTOR Signaling by Dietary Polyphenols in Obesity Prevention

Targeting mTOR Signaling by Dietary Polyphenols in Obesity Prevention

The effects of L-carnitine supplementation on glycemic markers in adults: A systematic review and dose-response meta-analysis

Contact Info

Product

Resources

About